Home
Clinical Trials
Rilzabrutinib for the Treatme...

Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

Last Updated: 2024-07-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

161 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-24

Study Completion Date

2024-04-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The first phase of this study will be a parallel, 12-week treatment, Phase 2, double-blind, 4 arm study to assess the safety and effectiveness of 3 oral doses of SAR444671 (rilzabrutinib), i.e. dose A, B and C, compared with placebo for decreasing the frequency and severity of itch and urticaria in male and female participants aged 18 years inclusive or older with CSU.

After completion of the double-blind phase of the study, participants will be given the option of enrolling in the 40-week open label extension (OLE) phase of the study. Participants will receive open-label rilzabrutinib at dose C (the dose may be modified based on the 12-week safety and efficacy data). Due to the fact that some participants may be receiving rilzabrutinib for the first time, all participants will be monitored at Week 14, Week 16, Week 20, and Week 24. Afterwards, participants will be monitored at Week 36 and Week 52.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Efficacy and Safety of TLL-018 in CSU Participants

NCT06396026

Chronic Spontaneous Urticaria

RECRUITING PHASE3

A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria

NCT05335499

Chronic Spontaneous Urticaria

COMPLETED PHASE2

Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.

NCT05373355

Chronic Spontaneous Urticaria

COMPLETED PHASE1

Antiplatelet Therapy in Chronic Urticaria

NCT06268470

Chronic Urticaria

ACTIVE_NOT_RECRUITING PHASE2

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

NCT03926611

Chronic Spontaneous Urticaria

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Spontaneous Urticaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rilzabrutinib dose A

dose A

Group Type EXPERIMENTAL

rilzabrutinib

Intervention Type DRUG

Tablet, oral use

Rilzabrutinib dose B

dose B

Group Type EXPERIMENTAL

rilzabrutinib

Intervention Type DRUG

Tablet, oral use

Rilzabrutinib dose C

dose C

Group Type EXPERIMENTAL

rilzabrutinib

Intervention Type DRUG

Tablet, oral use

Placebo

Matching placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Tablet, oral use

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rilzabrutinib

Tablet, oral use

Intervention Type DRUG

placebo

Tablet, oral use

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PRN1008/SAR444671

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who have a diagnosis of CSU refractory to H1-AH at the time of randomization
* Diagnosis of CSU ≥3 months prior to screening visit (Visit 1).
* The presence of itch and hives for ≥6 consecutive weeks at any time prior to screening visit (Visit 1) despite the use of H1-AH during this time period.
* Participants using a study defined H1-AH for CSU treatment. For participants on stable doses of non-study-approved H1-AH, investigators may switch participants to an equivalent dose of a study-approved H1-AH maintenance medication.
* Participants who are omalizumab naïve OR omalizumab-incomplete responders.
* Participants must be willing and able to complete a daily symptom e-diary for the duration of the study.
* During the 7 days before randomization: UAS7 ≥16 and ISS7 ≥8.
* Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria

* Clearly defined underlying etiology for CUs other than CSU (main manifestation being physical urticaria).
* Presence of skin morbidities other than CSU that may interfere with the assessment of the study outcomes.
* Participants with active atopic dermatitis (AD).
* Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the patient's participation in the study.
* Known or suspected immunodeficiency, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator.
* History of serious infections requiring intravenous (IV) therapy with the potential for recurrence (as judged by the Site Investigator) with less than 4 weeks interval between resolution of serious infection and first dose of study drug, or currently active moderate to severe infection at Screening (Grade 2 or higher), including active coronavirus disease 2019 (COVID-19).
* Live vaccine except Bacille Calmette Guerin-vaccination within 28 days prior to Day 1 or plan to receive one during the trial; Bacille Calmette Guerin-vaccination within 12 months prior to Screening.
* Active malignancy or history of malignancy within 5 years.
* Conditions that may predispose the participant to excessive bleeding
* Any participant with an uncontrolled disease state as judged by the Investigator, such as asthma, psoriasis, or inflammatory bowel disease, etc. that are typically treated with oral or parenteral corticosteroids
* Previous use of a BTK inhibitor.
* Has received any investigational drug (or is currently using an investigational device) within the 30 days before Day 1, or at least 5 times the respective elimination half-life time (whichever is longer).
* Previous exposure to another investigative drug for CSU.
* Positive for human immunodeficiency virus (HIV) antibody test.
* Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with positive DNA test result at screening or within 3 months prior to the screening visit.
* Positive hepatitis C antibody test result at screening or within 3 months prior to the screening visit.
* Tuberculosis infection.
* Any of significant laboratory abnormalities and ECG findings at the screening visit.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Investigational Site Number : 0320006

CABA, Buenos Aires, Argentina

Site Status

Investigational Site Number :0320006

CABA, Buenos Aires, Argentina

Site Status

Investigational Site Number : 0320002

CABA, Buenos Aires, Argentina

Site Status